Friday, July 16, 2010

FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal Related Events in Advanced Cancer Patients

FDA Accepts Submission Which Includes Data from Three Pivotal Phase 3 Trials

THOUSAND OAKS, Calif., July 16, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer. Filed in mid-May with the FDA, the Biologics License Application (BLA) submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three pivotal Phase 3 head-to-head trials versus Zometa(R) (zoledronic acid).

Read the rest of this entry

Posted in Press Releases

Thursday, July 15, 2010

Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer

THOUSAND OAKS, Calif., July 15, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced the appointment effective Sept. 1 of Jonathan M. Peacock as chief financial officer (CFO). He will be responsible for Amgen’s finance and investor relations operations. Peacock will report to Kevin W. Sharer, Amgen’s chairman and chief executive officer, and will succeed Michael A. Kelly, who served as acting CFO since May 2010.

Read the rest of this entry

Posted in Press Releases

Wednesday, July 14, 2010

Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients for Better Outcomes

THOUSAND OAKS, Calif. and WASHINGTON, July 14, 2010 /PRNewswire via COMTEX/ —

The Amgen Foundation is supporting an online competition with Ashoka’s Changemakers to find the best solutions that elevate patients’ voices to improve health outcomes globally.

Read the rest of this entry

Posted in Press Releases